Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
BioAge Labs, Inc. (BIOA)
Last bioage labs, inc. earnings: 8/3 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.bio-amber.com
Company Research
Source: PR Newswire
STOCKHOLM, Sweden, Jan. 26, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation to the European Medicines Agency (EMA) for a once every four weeks intravenous (IV) infusion maintenance dosing for lecanemab. In the EU, lecanemab is indicated for the treatment of patients with a clinical diagnosis of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (early Alzheimer's disease) who are apolipoprotein E e4 (ApoE e4[1]) non-carriers or heterozygotes with confirmed amyloid pathology.[2] Lecanemab is currently licensed as an IV infusion with a dosing regimen of once every two weeks (10 mg/kg). Eisai's submission states that following the initial dosing regimen of once every two weeks, after 18 months, patients will be transitioned to the maintenance dosing regimen of once every four weeks. Treatment with lecanemab should be discontinued once the pati
Show less
Read more
Impact Snapshot
Event Time:
BIOA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIOA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIOA alerts
High impacting BioAge Labs, Inc. news events
Weekly update
A roundup of the hottest topics
BIOA
News
- BioAge Labs (NASDAQ:BIOA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- BioAge Labs (NASDAQ:BIOA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.MarketBeat
- BioAge Labs (NASDAQ:BIOA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BIOA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen<MarketBeat
- BioAge Announces Pricing of Upsized $115.0 Million Public OfferingGlobeNewswire
- BioAge Labs plans up to $75M public stock offering; shares down [Seeking Alpha]Seeking Alpha
BIOA
Earnings
- 11/6/25 - Beat
BIOA
Sec Filings
- 2/2/26 - Form 144
- 1/22/26 - Form 8-K
- 1/22/26 - Form 424B5
- BIOA's page on the SEC website